WO2003073988A3 - Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof - Google Patents

Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof Download PDF

Info

Publication number
WO2003073988A3
WO2003073988A3 PCT/US2003/006061 US0306061W WO03073988A3 WO 2003073988 A3 WO2003073988 A3 WO 2003073988A3 US 0306061 W US0306061 W US 0306061W WO 03073988 A3 WO03073988 A3 WO 03073988A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosides
glycuronamides
fluoxetine
analogs
orthoester
Prior art date
Application number
PCT/US2003/006061
Other languages
French (fr)
Other versions
WO2003073988A2 (en
Inventor
Michael F Holick
Halasya Ramanathan
Original Assignee
A & D Bioscience Inc
Michael F Holick
Halasya Ramanathan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & D Bioscience Inc, Michael F Holick, Halasya Ramanathan filed Critical A & D Bioscience Inc
Priority to EP03713755A priority Critical patent/EP1487460A2/en
Priority to US10/506,012 priority patent/US7217696B2/en
Priority to AU2003217791A priority patent/AU2003217791A1/en
Priority to CA002478093A priority patent/CA2478093A1/en
Publication of WO2003073988A2 publication Critical patent/WO2003073988A2/en
Publication of WO2003073988A3 publication Critical patent/WO2003073988A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Abstract

Disclosed are glycosides, orthoester glycosides and glycuronamides of fluoxetine and analogs thereof to treat conditions and diseases such as depression.
PCT/US2003/006061 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof WO2003073988A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03713755A EP1487460A2 (en) 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
US10/506,012 US7217696B2 (en) 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
AU2003217791A AU2003217791A1 (en) 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
CA002478093A CA2478093A1 (en) 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35988702P 2002-02-28 2002-02-28
US60/359,887 2002-02-28

Publications (2)

Publication Number Publication Date
WO2003073988A2 WO2003073988A2 (en) 2003-09-12
WO2003073988A3 true WO2003073988A3 (en) 2004-08-05

Family

ID=27788962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006061 WO2003073988A2 (en) 2002-02-28 2003-02-27 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof

Country Status (6)

Country Link
US (1) US7217696B2 (en)
EP (1) EP1487460A2 (en)
CN (1) CN1649600A (en)
AU (1) AU2003217791A1 (en)
CA (1) CA2478093A1 (en)
WO (1) WO2003073988A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
US20050153928A1 (en) * 2002-05-07 2005-07-14 Holick Michael F. Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
JP4808453B2 (en) * 2005-08-26 2011-11-02 株式会社荏原製作所 Polishing method and polishing apparatus
EP3728280B1 (en) 2017-12-21 2023-06-28 Pharmacytics B.V. Method for improving the oral bioavailability of a drug
CN110627664B (en) * 2018-06-25 2022-07-29 北京安博睿达医药科技有限公司 Novel fluoxetine analogue and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
WO1992018005A1 (en) * 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1029222A (en) 1963-11-28 1966-05-11 Beecham Group Ltd Derivatives of 6-aminopenicillanic acid
US4292425A (en) 1979-11-13 1981-09-29 Miles Laboratories, Inc. βGalactosyl-umbelliferone valproic acid conjugates
US4261974A (en) 1979-11-13 1981-04-14 Miles Laboratories, Inc. Valproic acid immunogen conjugates and antibodies thereto
IT1171432B (en) 1981-08-03 1987-06-10 Fidia Farmaceutici ORGANIC STARCHES DERIVED FROM NITROGEN LIPIDS USABLE AS DRUGS
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
JPS59155381A (en) * 1983-02-22 1984-09-04 Kyorin Pharmaceut Co Ltd Benzoquinolizinecarboxylic acid derivative and its preparation
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4751219A (en) 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
IT1190133B (en) 1986-06-19 1988-02-10 Chiesi Farma Spa VALPROIC ACID AND (E) -2-VALPROENOIC ACID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4855463A (en) 1986-12-15 1989-08-08 Iowa State University Research Foundation, Inc. Method of producing water-soluble glucuronic acid derivatives of vitamin A
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US4774230A (en) * 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
FR2676058B1 (en) 1991-04-30 1994-02-25 Hoechst Lab GLYCOSYLATED PRODUCTS, THEIR PREPARATION PROCESS AND THEIR USE IN THE TREATMENT OF CANCERS.
US5432260A (en) 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
US5179093A (en) * 1991-05-10 1993-01-12 Schering Corporation Quinoline-diones
US5977326A (en) 1991-08-06 1999-11-02 Salford Ultrafine Chemicals And Research Limited Process for making morphine-6-glucuronide or substituted morphine-6-glucuronide
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
MX9206309A (en) 1991-11-04 1994-05-31 David Rubin METHOD AND COMPOSITION TO TREAT TUMORS THAT HAVE HIGH ACTIVITY OF THYROSINASE.
US5292899A (en) * 1991-11-27 1994-03-08 Synthetic Technology Corporation Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5412083A (en) * 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5679667A (en) 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
WO1994011030A1 (en) 1992-11-13 1994-05-26 The Ohio State University Research Foundation C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide
CA2152163A1 (en) * 1992-12-29 1994-07-07 Michael F. Holick Use of vitamin d glycosides for the treatment or prevention of osteoporosis
CA2134549A1 (en) * 1993-03-22 1994-09-29 Bruce F. Johnson Method for making 2-fluoro-2 deoxyglucose
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5436253A (en) * 1993-09-08 1995-07-25 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives and mycotic infections
EP0729363B1 (en) * 1994-06-27 2003-02-19 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US5612317A (en) 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5677286A (en) 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6313106B1 (en) 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5760072A (en) 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
AUPN978296A0 (en) 1996-05-10 1996-05-30 Gray, Bruce N Targeted hysteresis hyperthermia as a method for treating cancer
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5808111A (en) 1997-05-06 1998-09-15 The Ohio State Research Foundation Stable acitretinoid compounds
US6043367A (en) 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
AU777770C (en) * 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
AU2001225363A1 (en) * 2000-01-14 2001-07-24 Strakan Limited Glycosides and orthoester glycosides of glucocorticoids and uses thereof
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
US6548484B1 (en) * 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
US20040087559A1 (en) * 2000-09-22 2004-05-06 Schwartz Gary G. Methods for prevention and treatment of cancer
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003082301A1 (en) 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003086312A2 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
US20050153928A1 (en) * 2002-05-07 2005-07-14 Holick Michael F. Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
WO1992018005A1 (en) * 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] LEMBERGER L. ET AL: "Fluoxetine: clinical pharmacology and physiologic disposition", XP002979054, accession no. STN Database accession no. 1985:400111 *
J. OF CLINICAL PSYCHIATRY, vol. 46, no. 3, 1985, pages 14 - 19 *

Also Published As

Publication number Publication date
AU2003217791A8 (en) 2003-09-16
US20050130908A1 (en) 2005-06-16
US7217696B2 (en) 2007-05-15
CA2478093A1 (en) 2003-09-12
WO2003073988A2 (en) 2003-09-12
EP1487460A2 (en) 2004-12-22
CN1649600A (en) 2005-08-03
AU2003217791A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2006037024A3 (en) Salts of decitabine
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
AU2003253217A1 (en) Composition for heart disease, method to prepare same and uses thereof
WO2002014315A3 (en) Substituted pyrazoles
IL168487A (en) Quinolin-, isoquinolin- and quinazolin-oxyalkylamides , fungicidal compositions comprising them, process for their preparation and methods of using them to combat fungi
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2004009034A3 (en) Thiomolybdate analogues and uses thereof
WO2005123043A3 (en) Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
AU2003255621A1 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
EP1613269A4 (en) Compositions, methods and kits relating to her-2 cleavage
AU2003223304A1 (en) Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
WO2003073988A3 (en) Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2005110009A8 (en) COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
WO2006078833A3 (en) Novel coumarin derivatives as ion channel openers
WO2004026892A3 (en) Fragmentation of dna
WO2003079980A3 (en) Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2478093

Country of ref document: CA

Ref document number: 10506012

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1435/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003713755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038094967

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003713755

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP